Several researches use antagonist drugs of PPARɣ to inhibit adipocyte generation, such as bisphenol-A-diglyceryl ether (BADGE), SR10171, and Oleuropein; all of which have been proved to inhibit the expression of PPARɣ in BMSCs, inhibit adipocyte generation, and enhance BMSCs osteogenic differentiation, thus relieving osteoporosis [14, 19]. Here, PPARA is linked to osteoporosis.